Alpha Tau Medical Ltd. (NASDAQ:DRTS) Stock Has Consensus Price Target of $15.40 According to Analysts

Alpha Tau Medical Ltd. (NASDAQ:DRTS) has earned a consensus recommendation of “Hold” from the eight analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $15.40.

Several brokerages have recently commented on DRTS. Benchmark reissued a “buy” rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Barclays raised their target price on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, September 3rd. Zacks Research downgraded shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Thursday. Finally, HC Wainwright boosted their price target on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th.

Insider Activity at Alpha Tau Medical

In other news, CFO Raphi Levy sold 17,730 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $14.00, for a total transaction of $248,220.00. Following the sale, the chief financial officer owned 90,180 shares in the company, valued at approximately $1,262,520. This trade represents a 16.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 39.50% of the stock is owned by insiders.

Institutional Trading of Alpha Tau Medical

Hedge funds have recently made changes to their positions in the stock. Everhart Financial Group Inc. purchased a new position in Alpha Tau Medical in the second quarter worth $126,000. Principal Financial Group Inc. purchased a new stake in Alpha Tau Medical during the first quarter valued at about $132,000. Finally, Renaissance Technologies LLC purchased a new stake in Alpha Tau Medical during the first quarter valued at about $286,000. 2.65% of the stock is owned by institutional investors.

Alpha Tau Medical Price Performance

Alpha Tau Medical stock opened at $12.62 on Thursday. Alpha Tau Medical has a 52 week low of $3.43 and a 52 week high of $15.79. The business has a 50-day simple moving average of $14.47 and a 200 day simple moving average of $11.73. The company has a quick ratio of 7.79, a current ratio of 11.09 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -12.13 and a beta of 1.22.

Alpha Tau Medical (NASDAQ:DRTS) last announced its earnings results on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.36). On average, research analysts forecast that Alpha Tau Medical will post -1.05 earnings per share for the current fiscal year.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on developing localized radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver high-energy alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses implanted radium-224 sources that generate short-lived alpha-emitting atoms. These atoms diffuse through the treated tumor and can damage cancer cells over a localized area.